论文部分内容阅读
目的:观察健肝颗粒Ⅱ方联合恩替卡韦对HBe Ag阳性慢性乙型肝炎(CHB)患者外周血T淋巴细胞亚群的影响。方法:将HBe Ag阳性CHB患者300例随机分为对照组和治疗组各150例,治疗组采用健肝颗粒Ⅱ方联合恩替卡韦治疗,对照组单用恩替卡韦治疗。观察比较2组治疗前及治疗12周、24周、52周外周血T淋巴细胞亚群的变化。结果:治疗前2组CD3+、CD4~+、CD8~+T细胞数及CD4~+/CD8~+比值比较,差异无统计学意义(P>0.05);治疗组CD3+、CD4~+、CD8~+T细胞数及CD4~+/CD8~+比值从治疗12周起及其后各时间点较治疗前升高,差异具有统计学意义(P<0.01);对照组CD3+、CD4~+、CD8~+T细胞数及CD4~+/CD8~+比值从治疗24周起及其后各时间点较治疗前升高,差异具有统计学意义(P<0.05);治疗组各指标在各对应时间点的升高幅度均大于对照组,差异具有统计学意义(P<0.05)。结论:健肝颗粒Ⅱ方联合恩替卡韦治疗HBe Ag阳性CHB可提高患者外周血CD3+、CD4~+、CD8~+T细胞计数及CD4~+/CD8~+比值,提高患者细胞免疫功能,其疗效优于单用恩替卡韦。
Objective: To observe the effect of Jiangan Parti combined with entecavir on peripheral T lymphocyte subsets in patients with HBeAg-positive chronic hepatitis B (CHB). Methods: 300 HBeAg-positive CHB patients were randomly divided into control group and treatment group, 150 cases each. The treatment group was treated with Jiangan Granule Ⅱ combined with entecavir, while the control group was treated with entecavir alone. The changes of T lymphocyte subsets in peripheral blood before and 12 weeks, 24 weeks and 52 weeks after treatment in the two groups were observed and compared. Results: There was no significant difference in the number of CD3 +, CD4 +, CD8 + T cells and the ratio of CD4 ~ + / CD8 + between the two groups before treatment (P> 0.05) + T cells and CD4 ~ + / CD8 ~ + ratio increased from the 12th week after treatment and before the treatment, the difference was statistically significant (P <0.01); the control group CD3 +, CD4 ~ +, CD8 ~ + T cells and the ratio of CD4 ~ + / CD8 ~ + increased from 24 weeks after the treatment and all the time points before treatment, the difference was statistically significant (P <0.05); the treatment group indicators at each corresponding time The increase of point was larger than that of the control group, the difference was statistically significant (P <0.05). Conclusion: Combination of JGG Ⅱ and entecavir can improve the ratio of CD4 + / CD8 + and CD3 +, CD4 +, CD8 + T cells in peripheral blood of patients with HBeAg-positive CHB, and improve the cellular immune function of patients Entecavir alone.